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OBJECTIVES: To estimate the costs associated with juvenile idiopathic arthritis
(JIA) for Russia in 2009. METHODS: We used the standard cost of illness (COI)
method adopting the viewpoint of the payers (national and regional governments).
The data was obtained from the national statistics, registries, expert panel inter-
views and literature. The costs were calculated for the total population of JIA pa-
tients in Russia in 2009. We calculated direct medical costs (based on national
reimbursement rates and regional data on drug costs), non-medical costs (social
benefits expenditures) and indirect costs –productivity loss due to the necessity of
providing care for patients by parents. Indirect costs were assessed using friction
costs method. RESULTS: The total costs of JIA in Russia in 2009 was 1.175 billion
RUR (€28,48 mln), or 76,013 RUR (€1843) per patient per year. The highest per person
costs were attributed to patients with systemic JIA – 189,489 RUR (€4594), the
lowest - with oligoarticular type of JIA (40,223 RUR (€975)).The costs for handi-
capped child were 3.9 times higher than for those without disability, mostly be-
cause of different social benefits. The direct medical costs accounted for 31,5% of
total spending, direct non-medical costs – for 55,6%, and indirect costs – for 12,8%.
The share of direct non-medical costs in the overall spending was lower in less
severe patients: 58.3% for the systemic JIA, 57.7% for the polyarticular and 46.4% for
the oligoarticular type of JIA. Direct nonmedical costs represented 75.8% of total
costs for handicapped child versus 42.8% in patient without such status.
CONCLUSIONS: JIA represents significant social and economic burden for the state.
The costs for handicapped child are several times higher than for the one without
disability due to social benefits payments.
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THE SOCIETAL COST FOR RA BEFORE AND AFTER THE INTRODUCTION OF
BIOLOGICAL DRUGS- A SWEDISH NATIONAL REGISTER STUDY FOR 1990-2010
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OBJECTIVES: To study the total socioeconomic impact of rheumatoid arthritis (RA)
in Sweden 1990-2010 and to discuss the changes in costs during this period. The
period is deliberately chosen to cover 10 years before and 10 years after the intro-
duction of biological drugs, TNF-alfa inhibitors. METHODS: A prevalence based
cost of illness study based on data from official statistics. RESULTS: The total
socioeconomic cost of RA was 4.3 billion Swedish SEK (SEK) in 1990, adjusted to the
price level of 2010. This cost was raised to 5.8 billion SEK in 2010. The increase was
mainly due to augmented direct costs for pharmaceuticals. During these 20 years,
the drug costs increase from 10.4 percent of direct costs, to 75 percent of direct
costs in 2010. Of the total costs, drug costs increase from representing 3 to 32
percent. Consequently, the amount of costs that is taken up by indirect costs for RA
is lowered from 75 percent in 1990 to 58 percent in 2010. A decline is also seen in the
amount of costs that are taken up by costs for care for RA patients. CONCLUSIONS:
The relation between direct and indirect costs for RA has changed dramatically
during the last 20 years with an all rising direct cost for pharmaceuticals. There is
a decrease in indirect costs and costs for care which however does not offset the
increase in costs for pharmaceuticals.
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OBJECTIVES: A cost of illness study (COI) evaluates the direct, indirect and intan-
gible costs of a given disease in monetary terms. Depending on perspective, it
consists of different elements, and it values identical cost contents in different
ways. The social perspective takes account of all cost factors from the point of view.
The trends of previous years in Hungary increase the value of COI studies of soci-
etal perspective in the health care-related decision-making process. Several meth-
ods are available for the evaluation of the chronic diseases’ total costs in socially-
oriented COI studies. In this analysis, our aim is – through the example of the
chronic disease rheumatoid arthritis – to present and compare the results of dif-
ferent COI studies from different data resources, furthermore, to identify the ap-
plicability and limits of these studies through the example of rheumatoid arthritis
(RA). METHODS: The value and ratio of indirect cost of RA in Hungary was esti-
mated in three different approaches: 1. International and national published data
from comprehensive review was analyzed in same structure. 2. From ‘Top down’
estimation’s approach the indirect costs of RA was defined from public macro data.
3. From ‘Botton up’ estimation’s approach the indirect costs of RA was defined from
survey with questionnaire among RA patients. RESULTS: The comparison of the
listed resources alongside identical dimensions indicates that the tendencies are
similar although there are significant differences in the order of magnitude.
CONCLUSIONS: Decisions about health care resource allocations affect social wel-
fare. In reimbursement decisions the Hungarian National Health Insurance Fund
(NHIF) uses the payor’s perspective, but in the ranking and evaluation of health
technologies and therapies the societal perspective represents the basis for opti-
mization. COI studies can help in the identification of decision-making focal points,
although this necessitates the assessment and standardization of the applicable
methodologies.
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OBJECTIVES: To describe indirect resource utilization for inpatient ankylosing
spondylitis (AS) patients treated in tertiary public health facilities over a 1-year
period in Turkey, and demographic factors and disease activity scores associated
with indirect costs. METHODS: Medical records of 650 prevalent AS patients at-
tending seven centers at tertiary health care institutions nationwide were exam-
ined to assess annual indirect health care costs. Eligible patients were age18 and
diagnosed with AS for at least 12 months. We assessed relevant indirect cost-
related variables and activities, and actual costs. Multivariate regression was used
to determine the effects of demographic factors on indirect costs. The Pearson
correlation matrix and the association between disease activity scores and indirect
costs were assessed. RESULTS: Average AS patient age was 40.1 11.33 standard
deviation (SD) years and 35% of patients were female. 55% were employees, of
which 59% had employer permission to miss work (average 17 days annually) due
to AS, costing patients an average €412 annually due to workday loss as calculated
based on income level. 2% of patients had other AS-related consultations not cov-
ered by insurance (acupuncture, homeopathic, other), bringing their average an-
nual burden to a2,482. 10.46% of AS patients incurred additional AS-related costs
(e.g. need for new car, apartment, special equipment), spending an additional
a1,978 per year. 6.92% of patients required caregivers, costing €546 annually. Mul-
tivariate regression showed that age and gender played no significant role related
to the increase in indirect costs. Patients needing AS related equipments reported
significantly higher Global Disease Activity (GDA), visual analog scale (VAS), Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) and lower EuroQoL health
status (EQ-5D) scores. CONCLUSIONS: AS represents a considerable economic bur-
den to Turkey. Studies assessing chronic disease costs, especially in developing
nations, are important to determine efficient allocation of the limited resources in
such regions.
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OBJECTIVES: To estimate risk-adjusted health care costs and identify associated
risk factors for rheumatoid arthritis (RA) expenditures in Turkey using real-world
data. METHODS: This study used research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Incident cases of adult RA
patients with two RA visits at least 60 days apart, identified between June 1, 2010
and December 31, 2010, were required to have no RA diagnosis before June 1, 2010,
with at least 1 year of continuous enrollment forthe baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
theselected patients. RESULTS:Among 693 patients (mean age: 52.08; female: 80%),
19.6% were age 18-39, 60.9% were 40-64 years and 19.5% were age 65 or older. RA
diagnosis was most prevalent in the Marmara region (44%), followed by Central
Anatolia (23%), Aegean (16%), and Mediterranean (11%). Nearly 35%of RA patients
had at least one cardiovascular, diabetic, respiratory or allergy comorbid condition
prior to diagnosis. Most patients were prescribed non-COX inhibitors (79%) and
immunosuppressants (43%), and 4% of patients were prescribed disease-modifying
anti-rheumatic drugs (DMARDs). The total annual cost (a2,000) was comprised of
mainly pharmacy (a1,201), followed by outpatient (a411), and inpatient costs
(a361),and an average copay of a27. Prior comorbid conditions including diabetes,
respiratory disease as well as hospitalization, glucocorticoid and DMARD use sig-
nificantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of RA patients are significantly lower in Turkey rel-
ative to other countries in Europe, yet, pharmaceutical expenditures cover a sig-
nificant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for RA treatment.
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OBJECTIVES: Estimate risk-adjusted health care costs and identify associated risk
factors for rheumatoid arthritis (RA) expenditures in Turkey using real-world data.
METHODS: This study analyzed research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Adult prevalent RA patients
with two RA visits at least 60 days apart, identified between June 1, 2010 and
December 31, 2010, were required to have an RA diagnosis before June 1, 2010, with
at least 1 year of continuous enrollment for the baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
the selected patients. RESULTS: Among 1,920 patients (mean age: 53.91; female:
84%), 13.8% were age 18-39, 66.5% were 40-64 years and 19.7% were age 65 or older.
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RA diagnoses were most prevalent in the Marmara region (38%), followed by Ae-
gean (20%), Central Anatolia (21%), and Mediterranean (15%). Nearly 40% of RA
patients had at least one cardiovascular, diabetic, respiratory or allergy comorbid
condition prior to diagnosis. 5% of patients were hospitalized and 42% had at least
one outpatient visit during the pre-index period. Most patients were prescribed
non-COX inhibitors (78%) and immunosuppressants (71%), and 11% of patients
were prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients
(1%) had surgery prior to diagnosis. The total annual cost (a2,386) was comprised of
mainly pharmacy (a1,747), followed by outpatient (a360), and inpatient costs (a252),
and an average copay of 27a. Prior comorbid conditions including diabetes, respi-
ratory disease as well as hospitalization, glucocorticoid and DMARD use signifi-
cantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of RA patients are significantly lower in Turkey rel-
ative to other countries in Europe, yet, pharmaceutical expenditures cover a sig-
nificant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for RA treatment.
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OBJECTIVES: To determine indirect costs of rheumatoid arthritis (RA) due to work
loss, RA-related consultations, additional investments and caregivers in patients
who utilized public health care facility services in Turkey. Association between
indirect cost and disease activity scores such as Global Disease Activity (GDA),
EuroQoL health status (EQ-5D), visual analog scale (VAS), Health Assessment Ques-
tionnaire (HAQ) and the Routine assessment of patient index data (RAPID-3) were
also analyzed. METHODS: This cross-sectional study was performed in 10 univer-
sity rheumatology centers. Eligible patients were age18, diagnosed with RA for at
least 12 months according to the American College of Rheumatology (ACR) 1987
criteria. We assessed relevant indirect cost variables, activities associated with
indirect costs, and actual costs. Multivariate regression determined variables as-
sociated with higher indirect costs. Pearson correlation examined the association
between indirect costs and disease activity scores. RESULTS:A total of 698 patients
(82% female; mean age: 51.2  13.17 standard deviation [SD]) were questioned
regarding indirect RA costs. 14% were employees, of which 62% had employer
permission to miss work (average 27 days annually) due to RA, costing patients an
average €480 annually due to workday loss. 5.4% of patients had other RA-related
consultations not covered by insurance (acupuncture, homeopathic, other), bring-
ing their average annual burden to €1,600. 6.5% of RA patients incurred additional
RA-related costs (e.g. need for new car, apartment, special equipment), spending
an additional €1,640 in 1 year. 13.7% of patients required caregivers. The average
annual out-of-pocket amount paid to caregivers was €624. Multivariate regression
showed that age and gender were not significantly related to indirect costs. Pa-
tients needing caregivers reported significantly higher GDA, VAS, HAQ, RAPID-3
and lower EQ-5D scores. CONCLUSIONS: Indirect RA-related costs in Turkey are
significant. Comparative effectiveness studies on RA treatment should include di-
rect and indirect costs.
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OBJECTIVES: To estimate risk-adjusted health care costs and identify associated
risk factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world
data. METHODS: This study used research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Incident cases of adult AS
patients with two AS visits at least 60 days apart, identified between June 1, 2010
and December 31, 2010, were required to have no AS diagnosis before June 1, 2010,
with at least 1 year of continuous enrollment for the baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
the selected patients. RESULTS: Among 603 patients (mean age: 38.74; female:
44%), 58% were age 18-39, 39% were 40-64 years and 3% were age 65 or older. AS
diagnosis was most prevalent in the Marmara region (49%), followed by Central
Anatolia (22%), Aegean (13%), and Mediterranean (7%). Nearly 25% of AS patients
had at least one cardiovascular, diabetic, respiratory, allergy, Crohn’s disease and
rheumatoid arthritis comorbid condition prior to diagnosis. Most patients were
prescribed non-COX inhibitors (67%) and 7% of patients were prescribed disease-
modifying anti-rheumatic drugs (DMARDs). The total annual cost (a2,254) was com-
prised of mainly pharmacy (a1,738), followed by outpatient (a331), and inpatient
costs (a162), and an average copay of a23. Prior comorbid conditions including dia-
betes, respiratory disease as well as hospitalization, glucocorticoid and DMARD use
significantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey rela-
tive to other countries in Europe, yet, pharmaceutical expenditures cover a signif-
icant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for AS treatment.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs of rheumatoid arthritis (RA). Costs are supposed to increase with
increasing HAQ value. Therefore, we calculated direct (from health insurances
perspective) and productivity costs for five groups of patients according to their
HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assumption also in the
Slovak Republic. METHODS: This calculation was based on a retrospective cross-
sectional study. We included 119 patients with rheumatoid arthritis, aged 18-84
years either at working status, part-time disabled or full-time disabled. We used
prevalence-based cost-of-illness method type bottom-up, retrospectively review-
ing individual patient’s medical record. For calculation of productivity costs we
excluded patients older than 63 years of age (retirement pensioners). We used
friction costs approach (FCA) with defined friction period of 130 workdays, based on
patients’ absenteeism due to RA. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 50% and 70%, respectively,
based on the Slovak law on pension insurance. The height of average monthly
income in year 2010, €769 was used as denominator. Costs were expressed as mean
value per one patient with RA in each of the HAQ-group. RESULTS: Average pa-
tients= age was 49.5 years; average time from diagnosis was 12.3 years with mean
HAQ score 1.4 and mean DAS28 5.0. Mean annual medical direct costs, for each
HAQ-group, were €516, €468, €943, €1676, and €1466, respectively. Mean annual
indirect costs associated with productivity loss were €224, €1600, €1847, €2109, and
€2030, respectively. CONCLUSIONS: Direct and productivity costs for patients with
rheumatoid arthritis are closely related to the height of HAQ score. Total (direct and
productivity) annual mean costs were €2576.
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OBJECTIVES: To examine the resource utilization and direct costs of care associ-
ated with use of biologic agents therapy among prevalent rheumatoid arthritis (RA)
patients based on retrospective health care claims data. The database (EGB) is a
1/97 representative sample of the national claim database covering the whole
French population. METHODS: RA patients were identified as adults (age 18)
benefiting from full coverage (ALD eligibility criteria) for RA (ICD-10 M05-06) on
January 1, 2009 and still alive on December 31st, 2010. Biologics treated patients
(BTP) were defined as RA patients with 1 claim for biologics in 2010. All health
expenses were assessed from the payer’s perspective. A log-linear generalised
model was used to adjust the costs in comparing BTP versus patients not treated by
biologics (BNP). RESULTS: A total of 1,234 RA patients were identified of whom 199
(16.0%) were treated with biologics (BTP) including TNF inhibitors in 85% of cases. In
comparing patients not treated by biologics (BNP) versus BTP, the proportion of
male patients (24.1% versus 24.1% p0.99) nor the time since registration for RA
coverage (8.5 versus 9.0 years p0.33) were significantly different but BTP patients
were significantly younger 55.2 years  12.9 versus 64.1 years  14.5 (p0.0001).
The unadjusted per capita annual expenses of BTP were three times higher than in
BNP (15,581 € versus 4,892 € - p0.0001). Drug costs were respectively 8,477 € (54.4%
of total) versus 1,151€ (23.5% of total) (p 0.0001) and in-patient care 4,878 € (31.3%
of total) versus 1,696 € (34.7% of total) (p 0.0001). After adjustment for age, the
mean annual extra cost of patients on biologics was in the range 11,000 € - 12,000 €.
CONCLUSIONS: When compared to similar data prior to the era of biologics, the
structure of medical expenses in RA patients has shifted from in-patient care to-
wards drugs.
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OBJECTIVES: To examine the resource utilization and direct costs of care of prev-
alent rheumatoid arthritis (RA) patients using retrospective health care claims
data. METHODS: The EGB is a national representative 1/97 sample of individuals
covered by the French Health Insurance. Individuals presenting with RA (ICD-10 codes:
M05-06) can be identified in the database because they benefit from a full coverage. All
items of health care utilization and associated costs were assessed from the Health
Insurance perspective for 2010. The economic burden of RA was estimated by com-
paring medical expenses in the RA adult (18 years) population to a control group
matched on sex and age and using non parametric Mann-Whitney tests. RESULTS:
A total number of 1,296 RA patients were identified, i.e. a crude prevalence rate of
3.47/1000. The mean age was 63.3 years ( 14.8) and the sex ratio H/F was 0.33. A
proportion of 39.4% of patients benefitted from additional full coverage for other
co-morbibities, severe Hypertension (7.8%), NIDD (6.1%), Ischemic Heart Disease
(3%), Depression (1.9%) being the most frequent. Annual medical costs of the RA
population were 2 times higher than control (6,607 € versus 3,248 € p0.0001). The
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